The Michigan Department of Health and Human Services (MDHHS) shares a reminder that September 1, 2026, marks the beginning of the 2026-2027 respiratory syncytial virus (RSV) vaccination season for pregnant individuals along with the following update.
MDHHS follows the guidance provided by the recently updated recommendations from the American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP) and American College of Obstetricians & Gynecologists (ACOG).
Pfizer’s bivalent RSVpreF vaccine (Abrysvo) is the only RSV vaccine approved for use during pregnancy to prevent severe RSV disease in young infants. Pregnant individuals who did not receive the maternal RSV vaccine during previous RSV seasons are recommended to receive the RSV vaccine Abrysvo at 32 through 36 weeks gestation.
Updated recommendations for the 2026-2027 RSV season include:
- Pregnant individuals in most of the continental United States are eligible to receive the maternal RSV vaccine from September 1, 2026, through March 1, 2027, rather than through January 31, 2027. This extension of the RSV season is to provide adequate protection during the time of circulation of RSV.
Clinicians should clarify for the pregnant individual that if they decline the maternal RSV vaccination, the infant should receive a monoclonal antibody if under the age of 8 months and are born during or entering their first RSV season. Either monoclonal antibody product, nirsevimab or clesrovimab, may be used; there is no preferential recommendation for one over the other. The infant RSV season is October 1, 2026, through March 31, 2027, in most of the continental United States.
It is currently not recommended that pregnant patients who received the maternal RSV vaccine during the previous RSV season receive an additional dose during the 2026-2027 respiratory virus season. For patients vaccinated in a previous pregnancy, their infants should receive a monoclonal antibody during the respiratory virus season.
Please contact Dara J. Barrera, MSMS Director of Health Quality, Equity and Technology at 517-336-5766 or djbarrera@msms.org with your questions.